|Trade names||Myrbetriq (US), Betanis (JP), Betmiga (EU, RU)|
|Metabolism||Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase|
|Biological half-life||50 hours|
|Excretion||Urine (55%), faeces (34%)|
|Chemical and physical data|
|Molar mass||396.506 g/mol|
|3D model (Jmol)|
Mirabegron (trade name Myrbetriq // meer-BET-rik in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.
Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation.
Recently, mirabegron was shown to relax in vitro human and rabbit prostatic smooth muscle through activation of β3 adrenoceptor. The same group also showed that mirabegron promotes smooth muscle relaxation by α1 adrenergic receptor blockade.
Very common (>10% incidence) adverse effects include:
Common (1–10% incidence) adverse effects include:
- Dry mouth
- Urinary tract infection (UTI)
- Joint pain
- Back pain
- Upper respiratory tract infection (URTI)
- High heart rate
- Abdominal pain
- Neoplasms (cancers)
Rare (<1% incidence) adverse effects include:
- Blurred vision
- Abdominal distension
- Elevations in liver enzymes (GGTP, AST, ALT and LDH)
- Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
- Reproductive system disorders (e.g., vulvovaginal pruritus, vaginal infection)
- Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
- Stevens–Johnson syndrome associated with increased serum ALT, AST and bilirubin
- Urinary retention
- "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
- Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998). 48 (1): 25–32. PMID 22384458. doi:10.1358/dot.2012.48.1.1738056.
- Sacco, E; Bientinesi, R; et al. (Apr 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. PMID 24559030. doi:10.1517/17460441.2014.892923.
- "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)". ChEMBL. 5 July 2012. Retrieved 28 September 2012.
- "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013.
- "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013.
- Cypess, Aaron; Weiner, Lauren; Roberts-Toler, Carla; Elía, Elisa; Kessler, Skyler; Kahn, Peter; English, Jeffrey; Chatman, Kelly; Trauger, Sunia; Doria, Alessandro; Kolodny, Gerald (6 January 2015). "Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist". Cell Metabolism. 21 (1): 33–38. PMC . PMID 25565203. doi:10.1016/j.cmet.2014.12.009.
- Calmasini, F. B.; Candido, T. Z.; Alexandre, E. C.; D'Ancona, C. A.; Silva, D.; de Oliveira, M. A.; De Nucci, G.; Antunes, E.; Monica, F. Z. (2015). "The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?". Prostate. 75 (4): 440–447. doi:10.1002/pros.22930.
- Alexandre, E C; Kiguti, L R; Calmasini, F B; Silva, F H; da Silva, K P; Ferreira, R; Ribeiro, C A; Mónica, F Z; Pupo, A S (2015-10-01). "Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade". British Journal of Pharmacology. 173: 415–428. ISSN 1476-5381. doi:10.1111/bph.13367.